XML 46 R31.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions (Tables)
 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Business Combinations [Abstract]    
Schedule of Purchase Price Allocation
The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition ($ in millions):
 
2015
 
2014
 
2013
Trade accounts receivable
$
593.4

 
$
196.4

 
$
84.8

Inventories
524.9

 
174.0

 
10.4

Property, plant and equipment
740.9

 
91.0

 
45.7

Goodwill
9,862.2

 
1,643.6

 
517.5

Other intangible assets, primarily customer relationships, trade names and technology
5,058.3

 
1,658.2

 
334.3

In-process research and development
—

 
56.0

 
—

Trade accounts payable
(182.8
)
 
(54.7
)
 
(22.5
)
Other assets and liabilities, net
(1,827.6
)
 
(497.6
)
 
(66.2
)
Assumed debt
(417.0
)
 
(138.5
)
 
(21.2
)
Attributable to noncontrolling interest
—

 
—

 
(0.3
)
Net assets acquired
14,352.3

 
3,128.4

 
882.5

Less: noncash consideration
(47.3
)
 
—

 
—

Net cash consideration
$
14,305.0

 
$
3,128.4

 
$
882.5

  
Fair Values Of The Assets Acquired And Liabilities Assumed
The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the individually significant acquisition in 2015 discussed above, and all of the other 2015 acquisitions as a group ($ in millions):
 
Pall
 
Others
 
Total
Trade accounts receivable
$
509.7

 
$
83.7

 
$
593.4

Inventories
475.5

 
49.4

 
524.9

Property, plant and equipment
713.4

 
27.5

 
740.9

Goodwill
9,556.2

 
306.0

 
9,862.2

Other intangible assets, primarily customer relationships, trade names and technology
4,798.0

 
260.3

 
5,058.3

Trade accounts payable
(155.8
)
 
(27.0
)
 
(182.8
)
Other assets and liabilities, net
(1,855.2
)
 
27.6

 
(1,827.6
)
Assumed debt
(416.9
)
 
(0.1
)
 
(417.0
)
Net assets acquired
13,624.9

 
727.4

 
14,352.3

Less: noncash consideration
(47.3
)
 
—

 
(47.3
)
Net cash consideration
$
13,577.6

 
$
727.4

 
$
14,305.0
The following summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition for the individually significant acquisition in 2014 discussed above, and all of the other 2014 acquisitions as a group ($ in millions):
 
Nobel Biocare
 
Others
 
Total
Trade accounts receivable
$
124.9

 
$
71.5

 
$
196.4

Inventories
69.0

 
105.0

 
174.0

Property, plant and equipment
59.4

 
31.6

 
91.0

Goodwill
1,013.6

 
630.0

 
1,643.6

Other intangible assets, primarily customer relationships, trade names and technology
1,049.3

 
608.9

 
1,658.2

In-process research and development
—

 
56.0

 
56.0

Trade accounts payable
(30.8
)
 
(23.9
)
 
(54.7
)
Other assets and liabilities, net
(291.0
)
 
(206.6
)
 
(497.6
)
Assumed debt
(132.7
)
 
(5.8
)
 
(138.5
)
Net cash consideration
$
1,861.7

 
$
1,266.7

 
$
3,128.4
Results Of Operations If Acquisition Was Consummated
The unaudited pro forma information for the periods set forth below gives effect to the 2015 and 2014 acquisitions as if they had occurred as of January 1, 2014. The pro forma information is presented for informational purposes only and is not necessarily indicative of the results of operations that actually would have been achieved had the acquisitions been consummated as of that time ($ in millions except per share amounts):
 
2015
 
2014
Sales
$
22,491.2

 
$
23,310.3

Net earnings from continuing operations
2,741.6

 
2,571.3

Diluted net earnings per share from continuing operations
3.87

 
3.60